SCHEMBL6038783

SCHEMBL6038783

CN(CCOc1nccnc1NS(=O)(=O)c1ccc(Br)cc1)c1ccccc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGDR2 Q9Y5Y4 2/20 0.48
MEN1 O00255 4/20 0.45
KMT2A Q03164 4/20 0.45
F2 P00734 1/20 0.44
CCR4 P51679 1/20 0.42
EDNRB P24530 2/20 0.42
EDNRA P25101 2/20 0.42
CCR2 P41597 1/20 0.42
KDM4E B2RXH2 2/20 0.41
MAPT P10636 2/20 0.41
USP2 O75604 1/20 0.41
TSHR P16473 1/20 0.41
MAPK1 P28482 1/20 0.41
ALOX12 P18054 1/20 0.41
AR P10275 1/20 0.40
HTT P42858 2/20 0.40
LMNA P02545 1/20 0.40
POLB P06746 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
GAA P10253 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6038594 0.90 PTGDR2 (0.48) PTGDR2MEN1KMT2AF2CCR4
SCHEMBL6038924 0.89 PTGDR2 (0.60) PTGDR2MEN1KMT2AF2CCR4
SCHEMBL6038495 0.89 KMT2A (0.50) PTGDR2MEN1KMT2AF2EDNRB
SCHEMBL6039119 0.88 PTGDR2 (0.52) PTGDR2MEN1KMT2AF2EDNRB
SCHEMBL6038505 0.87 PTGDR2 (0.50) PTGDR2MEN1KMT2AF2EDNRB
SCHEMBL6038323 0.85 KDM4E (0.57) PTGDR2MEN1KMT2ACCR4KDM4E
SCHEMBL6039126 0.82 AR (0.50) MEN1KMT2AF2CCR4EDNRB
SCHEMBL6038939 0.81 AR (0.49) MEN1KMT2ACCR4EDNRBEDNRA
SCHEMBL6038980 0.77 KDM4E (0.67) MEN1KMT2AF2CCR4KDM4E
SCHEMBL6038440 0.76 KDM4E (0.58) MEN1KMT2ACCR4KDM4EMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060004010-A1 Ccr4 antagonist and medical use thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2006-01-05 US disclosed
EP-1541563-A1 CCR4 ANTAGONIST AND MEDICINAL USE THEREOF ONO PHARMACEUTICAL CO., LTD. (JP) 2005-06-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060004010-A1 Ccr4 antagonist and medical use thereof CCR4, CCR1, CCR9 PTGDR2 985/4885MEN1 2431/4885KMT2A 4190/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.